Together, our data support that MBD2 could be a promising prognostic marker for tumor metastasis, while strategies aimed at silencing MBD2 with siRNA-loaded liposomes could be a viable approach against tumor metastasis in clinical settings. Here, MBD2 is linked to neoplasm.